Tanım

An orphan drug is a medicine for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition that is rare or where the medicine is unlikely to generate sufficient profit to justify research and development costs. They are orphans because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions. The global orphan drugs market is set to grow by US$ 69 sırasında milyar 2021-2027, yıllık bileşik büyüme oranında büyüyor (CAGR) ile ilgili 5.5% tahmin dönemi boyunca, veri ve analiz şirketi StratejiHelix'e göre. Availability of exclusivity for orphan drugs, rising prevalence of rare diseases, favorable government policies are expected to boost the market growth in the coming years.

Rapor, döneme ilişkin güncel pazar büyüklüğü verilerini sağlar 2017-2020 ve tahmin 2027 covering key market aspects like sales value for orphan drugs. The global orphan drugs market is segmented on the basis of drug type, top selling drug, disease type, ve bölge. By drug type, it is categorized into biological drugs, and non-biological drugs. The biological drugs segment held the largest market share in 2020. By top selling drug, the orphan drugs market is divided into Revlimid, Tafinlar, Hemlibra, Darzalex, Kyprolis, Myozyme, Vyndaqel, Soliris, Ninlaro, Imbruvica, ve diğerleri. The Revlimid segment accounted for the largest market share in 2020. Based on disease type, the orphan drugs market is divided into oncology, blood disorders, central nervous system, respiratory system, immunomodulators, cardiovascular therapies, ve diğerleri.

The report has profiled some of the key players of the market such as AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., BioMarin Pharmaceutical Inc., Bristol-Myers Squibb Company, Celgene Corporation, CSL Behring GmbH, Eisai Co. Ltd., F. Hoffmann-La Roche AG, Incyte Corporation, Jiangsu Hengrui Medicine Co. Ltd., Johnson & Johnson, Novartis AG, Pfizer Inc., Sanofi S.A., Syros Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Vertex Pharmaceuticals Inc..

Rapor, bu sektörde faaliyet gösteren şirket ve kuruluşlar için paha biçilmez bir kaynaktır. It provides a cohesive picture of the orphan drugs market to help drive informed decision making for industry executives, kural koyucular, akademik, ve analistler.

Rapor Kapsamı

Drug type: biological drugs, and non-biological drugs
Top selling drug: Revlimid, Tafinlar, Hemlibra, Darzalex, Kyprolis, Myozyme, Vyndaqel, Soliris, Ninlaro, Imbruvica, ve diğerleri
Disease type: oncology, blood disorders, central nervous system, respiratory system, immunomodulators, cardiovascular therapies, ve diğerleri
Bölge: Kuzey Amerika, Asya Pasifik, Avrupa, ve Dünyanın Geri Kalanı (SIRA)
Düşünülen Yıllar: bu rapor dönemi kapsamaktadır 2017 ile 2027

Paydaşlar için Temel Faydalar

Get a comprehensive picture of the global orphan drugs market
Yerel veri ve analizlere dayanarak bölgesel stratejiler ve stratejik önceliklerin belirlenmesi
Büyüme sektörlerini ve yatırım eğilimlerini belirleyin
Understand what the future of the global orphan drugs market looks like
Rekabet ortamını ve fırsat penceresini belirleyin

İçindekiler

1. Pazar Tanımı
2. Araştırma Metodolojisi
3. Piyasa verileri & Görünüm
3.1 Market değeri
3.2 Piyasa Değeri Tahmini
4. Orphan Drugs Market by Drug Type
4.1 Biological Drugs
4.2 Non-Biological Drugs
5. Orphan Drugs Market by Top Selling Drug
5.1 Revlimid
5.2 Tafinlar
5.3 Hemlibra
5.4 Darzalex
5.5 Kyprolis
5.6 Myozyme
5.7 Vyndaqel
5.8 Soliris
5.9 Ninlaro
5.10 Imbruvica
5.11 Diğerleri
6. Orphan Drugs Market by Disease Type
6.1 Oncology
6.2 Blood Disorders
6.3 Central Nervous System
6.4 Respiratory System
6.5 Immunomodulators
6.6 Cardiovascular Therapies
6.7 Diğerleri
7. Orphan Drugs Market by Region
7.1 Kuzey Amerika
7.2 Asya Pasifik
7.3 Avrupa
7.4 Dünyanın Geri Kalanı (Sıra)
8. Şirket profilleri
8.1 AbbVie Inc.
8.2 Alexion Pharmaceuticals Inc.
8.3 Amgen Inc.
8.4 AstraZeneca plc
8.5 Biogen Inc.
8.6 BioMarin Pharmaceutical Inc.
8.7 Bristol-Myers Squibb Company
8.8 Celgene Corporation
8.9 CSL Behring GmbH
8.10 Eisai Co., Ltd..
8.11 F. Hoffmann-La Roche AG
8.12 Incyte Corporation
8.13 Jiangsu Hengrui Medicine Co., Ltd..
8.14 Johnson & Johnson
8.15 Novartis AG
8.16 Pfizer Inc.
8.17 Sanofi SA.
8.18 Syros Pharmaceuticals, A.Ş..
8.19 Takeda Pharmaceutical Co. Ltd..
8.20 Vertex Pharmaceuticals, A.Ş..
9. Ek
9.1 StratejiHelix Hakkında
9.2 Sorumluluk reddi beyanı